Skip to content

The Effect of Cognitive Functions on Upper Extremity Functionality in Parkinson's Patients

The Effect of Cognitive Functions on Upper Extremity Functionality in Parkinson's Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05872646
Enrollment
104
Registered
2023-05-24
Start date
2018-02-08
Completion date
2023-03-10
Last updated
2023-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment, Functional Disturbance, Parkinson, Upper Extremity Problem

Keywords

Parkinson, Cognitive function, Upper extremity

Brief summary

Parkinson's Disease (PD), first described by James Parkinson in 1817, is a progressive movement disorder that develops mainly as a result of the destruction of nigrostriatal dopaminergic neurons. The aim of our study is to determine the effect of cognitive functions on upper extremity functionality in individuals with Parkinson's Disease.

Detailed description

Parkinson's Disease (PD), first described by James Parkinson in 1817, is a progressive movement disorder that develops mainly as a result of the destruction of nigrostriatal dopaminergic neurons. Involvement of nigrostriatal dopaminergic neurons is associated with the motor manifestations of the disease. The most common of these symptoms are; resting tremor, bradykinesia, rigidity and balance disorder. However, non-motor symptoms related to the involvement of nervous system structures other than the dopaminergic nigrostriatal system can be observed in PD. However, due to the predominance of motor symptoms in PD, it took many years to notice cognitive changes. Traditionally, cognitive impairments in PD have been expected to occur in the advanced stages of the disease. However, cognitive impairments in the early stages are reported in approximately 30-35% of patients. Cognitive dysfunction is defined in PD, ranging from mild impairments in certain cognitive domains to severe dementia. Cognitive impairment primarily affects executive and visuospatial functions, and memory is secondarily affected. Executive functions are higher cognitive processes that use and modify information from many cortical sensory systems in the fore and hindbrain areas to modulate and teach behavior. The frontal cortex, especially the prefrontal cortex and its striatal connections are very important neuroanatomical regions for executive functions. The relationship between the effects of cognition and motor performance and parameters in groups such as the elderly, PD and Alzheimer's patients in which these centers are affected has been an issue that has attracted the attention of many researchers. Most of the studies have focused on the lower extremity performance of cognition. However , it has been reported that cognition has positive effects on upper extremity performance and early acquired upper extremity skills have positive effects on cognitive performance . The aim of our study is to determine the effect of cognitive functions on upper extremity functionality in individuals with Parkinson's Disease.

Interventions

DIAGNOSTIC_TESTclinical assessment

clinical staging

Sponsors

Pamukkale University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

patient and age-gender matched healthy groups

Eligibility

Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Having a diagnosis of Parkinson's Disease. * Not having hearing and vision problems. * To be able to take the commands required for the manual dexterity tests. * Agree to participate in the study.

Exclusion criteria

* Having undergone musculoskeletal surgery for the upper extremity. * Having vision and hearing problems. * Having an additional disease that may affect cognitive tests.

Design outcomes

Primary

MeasureTime frameDescription
Modified Hoehn Yahr Scale1 yearUsed for clinical staging of Parkinson's disease
Unified Parkinson's Disease Rating Scale1 yearUsed for the evaluation of clinical manifestations of Parkinson's disease
Parkinson's Disease Questionnaire-PDQ 391 yearUsed to assess the quality of life of Parkinson's patients

Secondary

MeasureTime frameDescription
Stroop Test1 yearmeasures the selective attention ability of individuals
Nine Hole Peg Test1 yearTo assess manuel dexterity
Wechsler Memory Scale-Revised1 yearTo assess attention, learning, memory and working memory in individuals aged 16-89
Dexterity Questionnaire-241 yearTo assess manuel dexterity

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026